Aspen Neuroscience has expanded its ongoing Phase 1/2a clinical trial by dosing two new groups of Parkinson’s disease…
Articles by Andrea Lobo
A European Medicines Agency (EMA) committee is recommending approval of Hopledo (IPX203) — an oral extended-release formulation of levodopa and…
Parkinson’s advocacy organizations are urging the newly established National Parkinson’s Project Advisory Council to move quickly to implement the…
The Michael J. Fox Foundation for Parkinson’s Research (MJFF) has granted $2.74 million to X-tosis to support the…
Clinical trials of UX-DA003, an experimental stem cell therapy for Parkinson’s disease developed by Unixell Biotechnology, can now…
A new personalized, adaptive deep brain stimulation (aDBS) system developed by researchers…
A $2.5 million research grant from The Michael J. Fox Foundation (MJFF) will help expand a Phase 2 clinical…
According to this year’s Parkinson’s Foundation State of the Community Survey, disease symptoms and medication knowledge are top concerns…
Scenic Biotech has joined the LRRK2 Investigative Therapeutics Exchange (LITE) program to study its PLA2G15 inhibitors as a potential…
UZ Leuven and KU Leuven, two institutions in Belgium, have introduced NeuroEXPLORER PET into clinical practice. The ultra-high-resolution PET scanner,…